ATE439453T1 - Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes - Google Patents

Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes

Info

Publication number
ATE439453T1
ATE439453T1 AT01942050T AT01942050T ATE439453T1 AT E439453 T1 ATE439453 T1 AT E439453T1 AT 01942050 T AT01942050 T AT 01942050T AT 01942050 T AT01942050 T AT 01942050T AT E439453 T1 ATE439453 T1 AT E439453T1
Authority
AT
Austria
Prior art keywords
diabetes
compositions
methods
identifying
test sets
Prior art date
Application number
AT01942050T
Other languages
English (en)
Inventor
Michael Byrne
Andrew Hill
S Wilson
Original Assignee
Genetics Inst Llc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst Llc, Gen Hospital Corp filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of ATE439453T1 publication Critical patent/ATE439453T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT01942050T 2000-06-05 2001-06-05 Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes ATE439453T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20970300P 2000-06-05 2000-06-05
PCT/US2001/018418 WO2001094636A2 (en) 2000-06-05 2001-06-05 Compositions, kits, and methods for identification and modulation of type i diabetes

Publications (1)

Publication Number Publication Date
ATE439453T1 true ATE439453T1 (de) 2009-08-15

Family

ID=22779905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01942050T ATE439453T1 (de) 2000-06-05 2001-06-05 Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes

Country Status (9)

Country Link
US (2) US20020039736A1 (de)
EP (1) EP1290227B1 (de)
JP (1) JP2004510411A (de)
AT (1) ATE439453T1 (de)
AU (1) AU2001275346A1 (de)
CA (1) CA2411473A1 (de)
DE (1) DE60139553D1 (de)
ES (1) ES2331407T3 (de)
WO (1) WO2001094636A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
EP1511690A4 (de) * 2002-05-16 2007-10-24 Univ Vanderbilt Verfahren zur vorhersage von autoimmunerkrankungen
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
JP2007515945A (ja) * 2003-05-30 2007-06-21 ロゼッタ インファーマティックス エルエルシー キネシン活性の調節因子を同定するための方法
EP1538219A1 (de) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Verfahren zur Diagnose oder Screening von Diabetes Mellitus Typ 1
EP1538218A1 (de) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Verfahren zur Diagnose oder Untersuchung entzündlicher Krankheiten
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
WO2009015472A1 (en) * 2007-07-30 2009-02-05 London Health Sciences Centre Research Inc. Methods to diagnose type 1 diabetes by measuring cytokine and/or chemokine expression profiles.
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP2419536A4 (de) * 2009-04-14 2012-09-05 Merck Sharp & Dohme Mikro-rna als biomarker für das eindringen von betazellen in die pankreasinseln
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
EP2596116A4 (de) 2010-07-23 2014-03-19 Harvard College Verfahren zur erkennung von autoimmun- oder autoimmunbezogenen erkrankungen oder leiden
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
EP3385717A3 (de) 2013-03-09 2018-10-24 Harry Stylli Verfahren zum nachweis von prostatakrebs
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
EP3191846A4 (de) 2014-09-11 2018-06-13 Harry Stylli Verfahren zum nachweis von prostatakrebs
CN116808063B (zh) * 2023-07-05 2023-12-12 中国医学科学院北京协和医院 糖尿病的标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE4209216A1 (de) * 1992-03-21 1993-09-23 Boehringer Mannheim Gmbh Humaner t-zell-marker ht6
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
AU2087799A (en) * 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells

Also Published As

Publication number Publication date
JP2004510411A (ja) 2004-04-08
WO2001094636A8 (en) 2002-01-10
US20050164233A1 (en) 2005-07-28
EP1290227A1 (de) 2003-03-12
CA2411473A1 (en) 2001-12-13
DE60139553D1 (de) 2009-09-24
ES2331407T3 (es) 2010-01-04
EP1290227B1 (de) 2009-08-12
WO2001094636A2 (en) 2001-12-13
US20020039736A1 (en) 2002-04-04
AU2001275346A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
ATE439453T1 (de) Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes
DE60141950D1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
DE69935211D1 (de) Diagnosesysteme auf basis von kulturen gemischter zellen
ATE272059T1 (de) Organische salze von isoleucyl-thiazolidin und - pyrrolidin und ihre verwendung als dipeptidylpeptidase-inhibitoren
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
DE60140865D1 (de) Zusammensetzungen und methoden zur identifizierung von krebszellen
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DE60330842D1 (de) Für den nachweis von nukleinsäuren kompetente biologische rohderivate
TR199900781T2 (xx) H�cre yap��ma inhibit�rleri
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
DE69823845D1 (de) Neue verbindungen zur erzeugung von chemilumineszenz mit hilfe einer peroxidase
DE60135104D1 (de) Mittel zum falschungssicheren von einem substrat
ATE468888T1 (de) Zusammensetzung zur färbung von keratinischen fasern enthaltend paraphenylendiamin-derivate mit einer pyrrolidinyl-gruppe
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
ATE421090T1 (de) Neues screening-verfahren von modulatoren der bakteriellen transkription
ATE428803T1 (de) Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände
ATE347105T1 (de) Verfahren, assay und kit zur quantifizierung von hiv-proteasehemmer
DE60043775D1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
ECSP066758A (es) Nuevas combinaciones de un agente antiemetico y un inhibidor de encefalinasa
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE513814T1 (de) Acridane-9-dithiocarboxylatderivate zur erzeugung von chemolumineszenz mit einer peroxidase
DE60029429D1 (de) Verfahren und zusammensetzungen zur überwachung der modifikation von natürlichen bindungspartners

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties